{"id":"NCT02799602","sponsor":"Bayer","briefTitle":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","officialTitle":"A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-30","primaryCompletion":"2021-10-25","completion":"2023-04-11","firstPosted":"2016-06-15","resultsPosted":"2023-02-24","lastUpdate":"2024-04-16"},"enrollment":1306,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Hormone-sensitive Prostate Cancer"],"interventions":[{"type":"DRUG","name":"BAY1841788 / darolutamide (ODM-201)","otherNames":[]},{"type":"DRUG","name":"Standard ADT (androgen deprivation therapy)","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel","type":"EXPERIMENTAL"},{"label":"Placebo + standard ADT + Docetaxel","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.","primaryOutcome":{"measure":"OS From Date of Randomization Until Death From Any Cause - Number of Events","timeFrame":"From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)","effectByArm":[{"arm":"Darolutamide (BAY1841788) + Docetaxel","deltaMin":229,"sd":null},{"arm":"Placebo + Docetaxel","deltaMin":304,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":300,"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Finland","France","Germany","Israel","Italy","Japan","Mexico","Netherlands","Poland","Russia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["36795843","35656777","35179323"],"seeAlso":["https://clinicaltrials.bayer.com/study/17777","http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":306,"n":652},"commonTop":["Alopecia","Fatigue","Arthralgia","Anaemia","Oedema peripheral"]}}